@article {2350,
	title = {Rationale, design and baseline characteristics of the PROJECT II study: PROpofol CardioproTECTion for Type II diabetics A randomized, controlled trial of high-dose propofol versus isoflurane preconditioning in patients undergoing on-pump coronary artery b},
	journal = {Contemporary Clinical Trials},
	volume = {30},
	number = {4},
	year = {2009},
	note = {ISI Document Delivery No.: 456NPTimes Cited: 1Cited Reference Count: 23Ansley, David M. Raedschelders, Koen Chen, David D. Y. Choi, Peter T.},
	month = {Jul},
	pages = {380-385},
	type = {Article},
	abstract = {Diabetes mellitus is a leading cause of death globally and results in significant morbidity and mortality following surgery. After cardiac surgery, diabetic patients are especially at risk for low cardiac output syndrome, which can quadruple the risk for postoperative death. Attempts to prevent low cardiac output syndrome have focused on increasing myocardial tolerance to ischemia (preconditioning), which involves the myocardial mitochondrial ATP-regulated K-ATP channel. G-protein initiation, nitric oxide synthase, and protein kinase C. Unfortunately, the signal transduction pathways required for preconditioning are corrupted in diabetes. Effective antioxidant intervention during ischemia-reperfusion appears important for preserving myocardial function: thus, alleviating oxidant-mediated post-ischemic injury by increasing antioxidant defenses (cardioprotection) is an alternative to preconditioning. Our previous work suggests that propofol(2,6-diisopropylphenol), an intravenous anesthetic with antioxidant potential, may confer cardioprotection. In this paper, we describe the rationale and methodology of the Pro-TECT II Study, a Phase II randomized controlled trial designed to explore the relationships of biomarkers of oxidative or nitrosative stress in diabetes, to determine the effect of propofol cardioprotection to counteract these effects in patients undergoing elective primary coronary bypass graft surgery with cardiopulmonary bypass, and to provide feasibility and sample size data needed to conduct Phase III trials. (C) 2009 Elsevier Inc. All rights reserved.},
	keywords = {15-F-2T-ISOPROSTANE FORMATION, antioxidant, apoptosis, CAPACITY, Cardiopulmonary bypass, Diabetes mellitus, EXPRESSION, F2-isoprostanes, HYPERGLYCEMIA, INJURY, MORTALITY, MYOCARDIAL-INFARCTION, Nitric oxide synthase type III, PREDICTORS, Propofol, SHORT-TERM},
	isbn = {1551-7144},
	url = {<Go to ISI>://000266853900014},
	author = {Ansley, D. M. and Raedschelders, K. and Chen, D. D. Y. and Choi, P. T.}
}
@article {2637,
	title = {Vanadium treatment of type 2 diabetes: A view to the future},
	journal = {Journal of Inorganic Biochemistry},
	volume = {103},
	number = {4},
	year = {2009},
	note = {ISI Document Delivery No.: 429EUTimes Cited: 20Cited Reference Count: 41Thompson, Katherine H. Lichter, Jay LeBel, Carl Scaife, Michael C. McNeill, John H. Orvig, Chris6th International Vanadium SymposiumJUL 17-19, 2008Lisbon, PORTUGALSp. Iss. SI},
	month = {Apr},
	pages = {554-558},
	type = {Proceedings Paper},
	abstract = {3-Hydroxy-2-methyl-4-pryone and 2-ethyl 3-hydroxy-4-pyrone (maltol and ethyl maltol, respectively) have proven especially suitable a ligands for vanadyl tons, fit potential insulin enhancing agents for diabetes mellitus. Both bis(maltolato)oxovanadium(IV) (BMOV), and the ethylmaltol analog, bis(ethylmaltolato)oxovanadium(IV) (BEOV), have the desired intermediate stability for pro-drug use, and have undergone extensive pie-clinical testing for safety and efficacy. Pharmacokinetic evaluation indicates a pattern of biodistribution consistent with fairly rapid dissociation and uptake, binding to serum transferrin for systemic circulation and transport to tissues, with preferential uptake in bone. These bis-ligand oxovanadium(IV) (VOL2) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy. BEOV has now completed Phase I and has advanced to Phase II clinical trials. In the Phase I trial, a ran-e of doses horn 10 mg, to 90 mg BEOV, given orally to non-diabetic volunteers, resulted in no adverse effects, all biochemical parameters remained within normal limits. In the Phase IIa trial, BEOV (AKP-020). 20 mg, daily for 28 clays, per os, in seven type 2 diabetic Subjects, was associated with reductions in fasting blood and glucose and \%HbA1c; improved responses to oral glucose tolerance testing, versus, the observed worsening of diabetic symptoms in the two placebo controls. (C) 2009 Elsevier Inc. All rights reserved.},
	keywords = {BIODISTRIBUTION, bis(ethylmaltolato)oxovanadium(IV), BIS(MALTOLATO)OXOVANADIUM(IV), CHEMISTRY, Diabetes mellitus, IN-VIVO, INSULIN SENSITIVITY, MALTOL, METAL-COMPLEXES, RATS, SERUM, SKELETAL-MUSCLE, SULFATE, VANADIUM},
	isbn = {0162-0134},
	url = {<Go to ISI>://000264904400011},
	author = {Thompson, K. H. and Lichter, J. and Lebel, C. and Scaife, M. C. and McNeill, J. H. and Orvig, Chris}
}
@article {5209,
	title = {Coordination chemistry of vanadium in metallopharmaceutical candidate compounds},
	journal = {Coordination Chemistry Reviews},
	volume = {219},
	year = {2001},
	note = {ISI Document Delivery No.: 478JQTimes Cited: 138Cited Reference Count: 119},
	month = {Sep-Oct},
	pages = {1033-1053},
	type = {Review},
	abstract = {The discovery of vanadium{\textquoteright}s insulin-like behaviour in vitro, and later of the orally available glucose- and lipid-lowering capability of these same compounds in vivo, has stimulated renewed interest in vanadium coordination chemistry. Besides the anti-diabetic effects for which it is now so well known, vanadium also exhibits a number of other therapeutic effects including anti-tumour and anti-inflammatory activities. In this review, emphasis will be on the most recent developments in the coordination chemistry of vanadium(III), (IV) and (V), as related to development of these compounds for pharmaceutical use. How best to measure bioactivity and the pharmaceutical relevance of accompanying increased oxidative stress will also be considered. (C) 2001 Elsevier Science B.V. All rights reserved.},
	keywords = {bioactivity, BIOLOGICAL-ACTIVITY, CANCER, CRYSTAL-STRUCTURE, Diabetes mellitus, DIABETES-MELLITUS, ESEEM, INSULIN-LIKE ACTIVITIES, OXIDATIVE STRESS, OXOVANADIUM(IV) COMPLEXES, OXYGEN-BRIDGED DIMER, PEROXO HETEROLIGAND VANADATES(V), pharmaceutical agents, RAY, SPECTROSCOPIC PROPERTIES, structure-activity relationships, TYROSINE PHOSPHORYLATION, vanadium complexes},
	isbn = {0010-8545},
	url = {<Go to ISI>://000171343600035},
	author = {Thompson, K. H. and Orvig, Chris}
}
